$XBI $125 -2%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Today the ASCO21 abstracts we're released after hours. You can see the full ASCO21 post which will be updated here.
Covid Updates
$VERU +3% Veru Enrolls First Patient in Phase 3 Clinical Trial of Sabizabulin (VERU-111) in High Risk Hospitalized COVID-19 Patients. source
Pipeline Updates
$ALBO -1% Albireo to Showcase New Data at 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. source
$XLRN -1% Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society 2021 International Conference. source
$XLRN -1% ACCELERON PRESENTS PRELIMINARY DATA FROM THE SPECTRA PHASE 2 TRIAL OF SOTATERCEPT IN PULMONARY ARTERIAL HYPERTENSION (PAH) AT THE AMERICAN THORACIC SOCIETY 2021 INTERNATIONAL CONFERENCE. source
$IMCR -5% Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B. source
$BTAI +1% BioXcel Therapeutics Announces FDA Acceptance for Filing of NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders I and II. source
$RETA +25% Reata Announces that The FDA Has Asked The Company to Request a Pre-NDA Meeting for Omaveloxolone for the Treatment of Friedreich’s Ataxia. source
Posted by DV
Comments